Drug manufacturers yesterday defended the legality of their restrictions on 340B contract pharmacy, in the wake of cease and desist letters from the U.S. Health Resources and Services Administration (HRSA).
Groups and individuals representing 340B covered entities, meanwhile, praised HRSA
…